B-cell depletion in the treatment of lupus nephritis
- 17 July 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 8 (9), 505-514
- https://doi.org/10.1038/nrneph.2012.141
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is clinically heterogeneous and affects multiple organs. Lupus nephritis is the most frequent severe manifestation of SLE. Conventional immunosuppressive therapy has increased the life expectancy of patients diagnosed with lupus nephritis, but only 70-80% of patients respond to this treatment and its adverse effects are considerable. B cells are central to the pathogenesis of SLE and are, therefore, an attractive therapeutic target. B-cell depletion has been used successfully to treat other autoimmune diseases, such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis, and many case reports and small nonrandomized trials of B-cell-depleting agents in patients with lupus nephritis have reported positive results. By contrast, two large placebo-controlled trials designed to investigate the efficacy of the B-cell-depleting agents rituximab and ocrelizumab as a treatment for lupus nephritis, failed to meet their primary efficacy end points (LUNAR and BELONG, respectively). This Review discusses the current evidence on the use of B-cell depletion in the treatment of lupus nephritis, which is derived from case studies and clinical trials including a total of over 800 patients.Keywords
This publication has 76 references indexed in Scilit:
- Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trialAnnals Of The Rheumatic Diseases, 2012
- Rituximab resistanceBest Practice & Research Clinical Haematology, 2011
- Treatment of systemic lupus erythematosus with epratuzumabBritish Journal of Clinical Pharmacology, 2011
- Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective studyArthritis Research & Therapy, 2010
- Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis TrialAnnals Of The Rheumatic Diseases, 2010
- Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisClinical Journal of the American Society of Nephrology, 2010
- Pathogenesis of kidney disease in systemic lupus erythematosusCurrent Opinion in Rheumatology, 2009
- BAFF: a local and systemic target in autoimmune diseasesClinical and Experimental Immunology, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004